Figure 2
From: Prevention of bone metastases and management of bone health in early breast cancer
Relative risk of disease recurrence in two clinical trials of adjuvant zoledronic acid. Forest plot of disease-free survival in the ABCSG-12 trial in premenopausal women with early breast cancer and in the ZO-FAST study in postmenopausal women with early breast cancer. Horizontal lines, 95% confidence intervals. ZOL, zoledronic acid. Data from Gnant and colleagues [15, 29] and Eidtmann and colleagues [14].